View on market: Stay Cautious, be with quality business:

Stocks declined in Asia at the start of a pivotal week for markets, with interest rate decisions due from the Federal Reserve, the European Central Bank and a host of their peers. The dollar edged higher and made gains against the yen, the euro and the offshore yuan in early trading. Shares fell in Japan, South Korea and Australia and equity futures indicated a likely drop to come for Hong Kong. The Indian benchmark indices fell in trade after a volatile day and snapped their two-week gaining streak on Friday. Brent crude continued to trade at sub-$80 levels at around $77 per barrel, while Nymex crude fell to $72.07 per barrel. At 6:40 a.m., the Singapore-traded SGX Nifty — an early barometer of India’s benchmark Nifty 50 — fell 0.17% to 18,559. ADRs indicated a gap down start for IT major such as Infosys Ltd. and Wipro Ltd.

Economic Calendar:

  • USD : CPI (MoM) (Nov) on 13th December, 2022
  • USD : Fed Interest Rate Decision on 15th December, 2022
  • INR : CPI (YoY) (Nov) on 12th December, 2022
  • INR : WPI Inflation (YoY) (Nov) on 14th December, 2022

Brokerage Radar:

JEFFERIES ON INDUSIND BK: Buy, TP raised to Rs 1600; Ready for next leg of re-rating; Expect loan growth to improve to +20% from FY24 & ROA towards 2% as new loan segments, initiatives on funding & credit quality checks pay off; Approval for extension to CEO key catalyst in Feb

MS ON BHARAT FORGE: OW, TP Rs 1035; Key focus on new business avenues such as defense, aerospace electric vehicles & aluminum light-weighting; Under its 2030 strategy, co expects to strengthen its core portfolio while expanding into new biz

NOUMURA ON HONEYWELL AUTO: Buy, TP Raised to Rs 50642; Preferred pick on India digitalization; Execution & margins to pick up as services/exports recover & semiconductor lead times reduce; Expect turnaround in 2HFY23F continuing into FY24F

Trading @55x, FY24F EPS

International Markets:

U.S & Europe

Particulars 09th December Chg. Chg.(%)
Nasdaq 11004.62 -77.38 -0.70
Dow 33476.46 -305.02 -0.90
FTSE 7476.63 4.46 0.06
CAC 6677.64 30.33 0.46
DAX 14370.72 106.16 0.74
Dow Fut.* 33434.00 -42.50 -0.13

Asian markets


Particulars 12th December Chg. Chg.(%)
SGX Nifty 18528.00 -63.00 -0.34
Nikkei 27821.12 -79.89 -0.29
Straits Times 3244.99 -0.98 -0.03
Hang Seng 19546.65 -354.22 -1.78
Shanghai 3187.09 -19.86 -0.62

ADR Watch:

Particulars 09th December  Chg.       Chg.(%)
Dr. Reddy 53.85 0.14 0.26
HDFC Bank 68.70 0.67 0.98
ICICI Bank 22.72 -0.13 -0.57
Infosys 18.49 -1.09 -5.57
Tata Motor 24.72 -0.24 -0.96
Wipro 4.71 -0.22 -4.46

Commodities & Currency

Particulars Current Price Chg.(%)
USD/INR 82.27 -0.18
Brent 76.36 -0.60
Gold 1799.60 -0.61
Silver 23.497 -0.93

FIIs & DIIs:

Particulars 09th December 08th December
FIIs    -158.01 -1131.67
DIIs 501.63 772.29

News Update:

Kalpataru Power Transmission: The company raised Rs 99 crore via allotment of non-convertible debentures on a private placement basis.

PSP Projects: The company received a letter of intent from Nila Spaces for a project worth Rs 121.51 crore to construct high-rise residential towers.

Emami: The company increased its shareholding in subsidiary Brillare Science from 77.53% to 80.59%.

Bank of Baroda: The bank hike MCLR rates in the range of 25-30 basis points across tenors, with effect from Dec. 12.

IDFC: The scheme of amalgamation for the merger of wholly owned subsidiary companies IDFC Alternatives, IDFC Trustee Co., IDFC Projects with IDFC became operative from Dec. 9. Bharti Airtel: After receipt of notice for conversion of FCCBs of principle value of $8.6 mn from certain holders of FCCBs, board members have approved allotment of 11.88 lakh shares at conversion price of Rs 521 per share to such FCCBs holders.

Himatsingka Seide: Board will meet on December 15 to consider fund raising up to Rs 108 crore. They will also consider an issue of NCDs up to Rs 500 crore, to identified investors.

NTPC: Commences commercial operations of first part capacity of 162.27 MW out of 230 MW Ettayapuram Solar PV Project.

Jaypee Power: Meeting of board to apprise the board of the recommendations of the audit committee to consider the proposal of divestment of Jaypee Nigrie Cement Grinding Unit.

Zydus Lifesciences: Receives two final approvals from the USFDA for Silodosin capsules and Pregabalin capsules The drugs will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India. Silodosin capsules had annual sales of $14 million in the United States according to IQVIA data. Pregabalin capsules had annual sales of $242 million in the United States according to IQVIA data.

Source: Moneycontrol, Bloomberg Quint, Investing

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited,
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting, or emailing with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website:
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL